|
US5525464A
(en)
|
1987-04-01 |
1996-06-11 |
Hyseq, Inc. |
Method of sequencing by hybridization of oligonucleotide probes
|
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
|
US5700637A
(en)
|
1988-05-03 |
1997-12-23 |
Isis Innovation Limited |
Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
|
|
US6054270A
(en)
|
1988-05-03 |
2000-04-25 |
Oxford Gene Technology Limited |
Analying polynucleotide sequences
|
|
US5871928A
(en)
|
1989-06-07 |
1999-02-16 |
Fodor; Stephen P. A. |
Methods for nucleic acid analysis
|
|
US5744101A
(en)
|
1989-06-07 |
1998-04-28 |
Affymax Technologies N.V. |
Photolabile nucleoside protecting groups
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US5800992A
(en)
|
1989-06-07 |
1998-09-01 |
Fodor; Stephen P.A. |
Method of detecting nucleic acids
|
|
CA2124087C
(en)
|
1991-11-22 |
2002-10-01 |
James L. Winkler |
Combinatorial strategies for polymer synthesis
|
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
|
US5795716A
(en)
|
1994-10-21 |
1998-08-18 |
Chee; Mark S. |
Computer-aided visualization and analysis system for sequence evaluation
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US20020065296A1
(en)
|
1999-01-13 |
2002-05-30 |
Bayer Corporation |
Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
|
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US7141581B2
(en)
|
1999-07-02 |
2006-11-28 |
Agouron Pharmaceuticals, Inc. |
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
|
|
TWI262914B
(en)
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
|
KR100881105B1
(ko)
|
1999-11-05 |
2009-02-02 |
아스트라제네카 아베 |
Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
|
|
ATE331514T1
(de)
|
1999-12-22 |
2006-07-15 |
Sugen Inc |
Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
|
|
JP3663382B2
(ja)
|
2000-02-15 |
2005-06-22 |
スージェン・インコーポレーテッド |
ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
|
|
BR0116452A
(pt)
|
2000-12-21 |
2003-09-30 |
Glaxo Group Ltd |
Composto, composição farmacêutica, uso de um composto
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
WO2003047579A1
(en)
|
2001-12-03 |
2003-06-12 |
Bayer Pharmaceuticals Corporation |
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
|
|
SE0104164L
(sv)
|
2001-12-11 |
2003-06-12 |
Ericsson Telefon Ab L M |
Högspännings-mos-transistor
|
|
NO317200B1
(no)
|
2002-08-09 |
2004-09-13 |
Best Practice Deployment As |
System for trafikkopplaering i et kjoretoy
|
|
NZ538982A
(en)
*
|
2002-09-27 |
2008-07-31 |
Oridis Biomed Forschungs Und E |
Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
|
|
US20060019256A1
(en)
*
|
2003-06-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
|
EP2210607B1
(en)
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
GB0411378D0
(en)
|
2004-05-21 |
2004-06-23 |
Astrazeneca Ab |
Pharmaceutical compositions
|
|
AU2006259583A1
(en)
|
2005-06-13 |
2006-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
|
WO2007047955A2
(en)
|
2005-10-21 |
2007-04-26 |
Bayer Healthcare Llc |
Methods for prediction and prognosis of cancer, and monitoring cancer therapy
|
|
US8329408B2
(en)
|
2005-10-31 |
2012-12-11 |
Bayer Healthcare Llc |
Methods for prognosis and monitoring cancer therapy
|
|
US20090215835A1
(en)
|
2005-10-31 |
2009-08-27 |
Scott Wilhelm |
Treatment of cancer with sorafenib
|
|
JP2009543797A
(ja)
|
2006-07-10 |
2009-12-10 |
エラン ファーマ インターナショナル，リミティド |
ナノ粒子ソラフェニブ製剤
|
|
WO2008082730A2
(en)
*
|
2006-09-19 |
2008-07-10 |
Novartis Ag |
Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
|
|
KR101667960B1
(ko)
*
|
2007-07-25 |
2016-10-20 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
암 치료에서 이용하기 위한 멀티키나아제 억제제
|
|
US20090062347A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched axitinib
|
|
US20090062368A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
|
NZ583790A
(en)
|
2007-09-10 |
2012-04-27 |
Cipla Ltd |
Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process
|
|
MX2010003329A
(es)
|
2007-09-26 |
2010-04-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-receptor de il-6.
|
|
WO2009054004A2
(en)
|
2007-10-22 |
2009-04-30 |
Natco Pharma Limited |
Process for the preparation of sorafenib
|
|
US20100256392A1
(en)
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
|
EP2220071A2
(en)
|
2007-11-21 |
2010-08-25 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
|
|
EP2252607A2
(en)
|
2008-02-21 |
2010-11-24 |
Generics [UK] Limited |
Novel polymorphs and processes for their preparation
|
|
WO2009106825A1
(en)
|
2008-02-27 |
2009-09-03 |
Cipla Limited |
Polymorphs of sorafenib and salts thereof
|
|
WO2009111061A1
(en)
|
2008-03-06 |
2009-09-11 |
Sicor Inc. |
Process for the preparation of sorafenib and salts thereof
|
|
EP2098521A1
(en)
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
|
WO2009124037A1
(en)
|
2008-03-31 |
2009-10-08 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing sunitinib and salts thereof
|
|
CA2724310A1
(en)
|
2008-06-23 |
2009-12-30 |
Natco Pharma Limited |
Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
|
|
CA2731605A1
(en)
|
2008-07-24 |
2010-01-28 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib and salts thereof and their polymorphs
|
|
US20110301113A1
(en)
|
2008-09-26 |
2011-12-08 |
Concert Pharmaceuticals Inc. |
Pyridineamine derivatives
|
|
WO2010039798A2
(en)
|
2008-09-30 |
2010-04-08 |
Teva Pharmaceutical Industries Ltd. |
Amorphous compositions of sunitinib base and l-malic acid
|
|
JP5439494B2
(ja)
*
|
2008-10-21 |
2014-03-12 |
バイエル ヘルスケア エルエルシー |
肝細胞癌と関連するシグネチャ遺伝子の同定
|
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
|
EP2186809A1
(en)
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
|
US10262103B2
(en)
*
|
2008-11-18 |
2019-04-16 |
Raphael LEHRER |
Individualized cancer treatment
|
|
US20100297676A1
(en)
*
|
2009-05-20 |
2010-11-25 |
Nodality, Inc. |
Methods for diagnosis, prognosis and methods of treatment
|
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
|
AU2010273254A1
(en)
|
2009-07-16 |
2012-02-02 |
Glaxo Wellcome Manufacturing Pte Ltd |
Treatment method
|
|
US20120232102A1
(en)
|
2009-09-30 |
2012-09-13 |
Chun-Fang Xu |
Methods Of Administration And Treatment
|
|
EP2470212A4
(en)
|
2009-10-01 |
2013-12-04 |
Csl Ltd |
METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA
|
|
WO2011047019A1
(en)
*
|
2009-10-13 |
2011-04-21 |
Yale University |
An objective, quantitative method to predict histological subtype in non-small cell lung cancer
|
|
US20120197019A1
(en)
|
2009-10-23 |
2012-08-02 |
Dharmesh Surendra Bhanushali |
Compositions and processes
|
|
UY33164A
(es)
|
2010-01-06 |
2011-08-31 |
Glaxo Wellcome Mfg Pte Ltd |
Metodo de tratamiento
|
|
WO2011100325A2
(en)
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
|
WO2011104555A2
(en)
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
|
WO2011128699A2
(en)
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
|
AR081364A1
(es)
|
2010-05-05 |
2012-08-29 |
Glaxo Wellcome Mfg Pte Ltd |
Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
|
|
WO2011146458A1
(en)
|
2010-05-18 |
2011-11-24 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
|
CA2816559C
(en)
|
2010-11-01 |
2018-02-13 |
Scinopharm (Kunshan) Biochemical Technology Co., Ltd. |
Processes for the preparation of 3-((pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
|
|
US9150547B2
(en)
|
2010-11-29 |
2015-10-06 |
Hetero Research Foundation |
Process for the preparation of pazopanib using novel intermediate
|
|
JP6009457B2
(ja)
|
2010-12-23 |
2016-10-19 |
ネクター セラピューティクス |
ポリマー−デスエチルスニチニブコンジュゲート
|
|
WO2012103060A1
(en)
|
2011-01-27 |
2012-08-02 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
|
WO2012116040A1
(en)
*
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
CN102283836B
(zh)
*
|
2011-06-27 |
2013-01-09 |
苏州大学附属第一医院 |
索拉非尼在制备治疗动脉瘤性自发性蛛网膜下腔出血后发生的早期脑损伤的药物中的应用
|
|
CN103764118A
(zh)
|
2011-06-28 |
2014-04-30 |
拜尔健康护理有限责任公司 |
含有索拉非尼的局部眼用药用组合物
|
|
KR20140067001A
(ko)
|
2011-08-08 |
2014-06-03 |
카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. |
생물지표 조성물 및 방법
|
|
WO2013043529A1
(en)
|
2011-09-19 |
2013-03-28 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
|
CN103826618A
(zh)
|
2011-09-30 |
2014-05-28 |
辉瑞大药厂 |
N-甲基-2-[3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基]苯甲酰胺的药物组合物
|
|
US20140322166A1
(en)
*
|
2011-12-12 |
2014-10-30 |
Stc. Unm |
Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia
|
|
US20140087362A1
(en)
*
|
2012-03-16 |
2014-03-27 |
Aladar A. Szalay |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
ES2813877T3
(es)
|
2013-08-28 |
2021-03-25 |
Crown Bioscience Inc Taicang |
Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos
|